Contribute Try STAT+ Today

The acceleration of investment in digital health and adoption of health-related apps triggered by the pandemic, which aimed to expand access at a time when access was difficult and health care needs were growing, may be harming the particularly important subset known as digital therapeutics (DTx).

Health apps constitute a broad category, focusing on everything from health and well-being to treatment of disease. They may be unvalidated or based on limited evidence, essentially a caveat emptor situation. Digital therapeutics, in contrast, deliver medical interventions using evidence-based, clinically evaluated software, with a focus on treating, managing, and preventing diseases and disorders such as asthma and musculoskeletal pain. A growing problem with digital therapeutics, a subset of which are prescribed by clinicians, is that they often have a less-than-rigorous evidence base than should be expected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment